Press release
Head and Neck Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Head and Neck cancer Treatment Landscape. Click here to read more @ Head and Neck cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Head and Neck Cancer Pipeline Report
* In May 2025, M.D. Anderson Cancer Center announced a clinical research study is to learn if RAD001 in combination with Tarceva (erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC). The safety of this drug combination will also be studied.
* In May 2025, Ascendis Pharma A/S conducted a study is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 /, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). After surgery, participants will receive local standard-of-care treatment and will be followed for safety, efficacy, and survival for up to 2 years.
* DelveInsight's Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Head and Neck Cancer treatment.
* The leading Head and Neck Cancer Companies such as Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., and others.
* Promising Head and Neck Cancer Therapies such as RiMO-301, Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug, Methotrexate, Afatinib, and others.
Discover groundbreaking developments in Head and Neck Cancer Therapies! Gain in-depth knowledge of key Head and Neck Cancer Clinical trials, emerging drugs, and market opportunities @ Head and Neck Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Head and Neck Cancer Emerging Drugs Profile
* Xevinapant: Debiopharm/Merck
Xevinapant is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins). IAP inhibitors restore sensitivity to apoptosis in cancer cells and thereby deprive them of one of their major resistance mechanisms. This class of products is therefore particularly suited to be combined with widely used but often sub-optimal chemo- and radiotherapy (CRT). As leader of the class, xevinapant established proof of efficacy in high-risk locally advanced squamous cell carcinoma of the head and neck (LASCCHN) patients for which the combination provided highly significant and sustainable clinical benefit as compared to CRT alone. Increasing tumor cell sensitivity to chemoradiotherapy constitutes a highly promising strategy for xevinapant which ultimately may improve treatment outcomes for these high-risk patients and other cancer patients currently treated with similar regimens. In addition to combination with CRT, xevinapant is also being investigated in combination with chemotherapy as well as checkpoint inhibitors. An exclusive license agreement has been granted to Merck in 2021 for its further development and commercialization. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Head and Neck cancer.
* Dostarlimab: GlaxoSmithKline
Dostarlimab, developed by GlaxoSmithKline (GSK), is a humanized monoclonal antibody that targets the programmed death-1 (PD-1) receptor, enhancing the body's immune response against various cancers, including head and neck cancer. It has shown promise in several clinical trials, particularly for cancers characterized by mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) statuses. Dostarlimab functions by inhibiting the interaction between PD-1 receptors on T-cells and their ligands (PD-L1) on tumor cells. This blockade allows T-cells to more effectively recognize and attack cancer cells, thereby promoting tumor regression. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Head and Neck cancer.
* Tigilanol tiglate: QBiotics Group Limited
It is a short-chain diterpene ester isolated from the seed of Fontainea picrosperma, with potential antineoplastic activity. Upon intratumoral administration, tigilanol tiglate disrupts mitochondrial functioning and induces mitochondrial swelling, which leads to oncolysis of tumor cells that are in direct contact of the agent. In addition, tigilanol tiglate activates protein kinase C (PKC) signaling cascade, which leads to an acute inflammatory response. This results in hypoxia and activates innate immune cells including neutrophils and macrophages, thereby further killing tumor cells. The activation of the beta-II isoform of PKC (PKC beta II) also increases tumor vasculature permeability, which leads to the destruction of tumor vasculature. Currently, the drug is in the Phase II stage of development to treat Head and Neck cancer.
* MEM-288: Memgen, Inc.
MEM-288 is an innovative oncolytic adenovirus developed by Memgen, Inc., designed as a cancer immunotherapy targeting solid tumors. It incorporates two key transgenes: human interferon beta (IFN) and a proprietary recombinant chimeric CD40 ligand (CD40L). This combination aims to enhance the immune system's response against cancer cells, particularly in patients whose tumors have not responded to existing therapies, such as checkpoint inhibitors. Currently, the drug is in the Phase I stage of development to treat Head and Neck cancer.
The Head and Neck Cancer Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Head and Neck Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Head and Neck Cancer Treatment.
* Head and Neck Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Head and Neck Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Head and Neck Cancer Market
Stay informed about the Head and Neck Cancer Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Head and Neck Cancer Unmet Needs [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Head and Neck Cancer Companies
Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc ., and others.
Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Head and Neck Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Transform your understanding of the Head and Neck Cancer Pipeline! See the latest progress in drug development and clinical research @ Head and Neck Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Head and Neck Cancer Pipeline Report
* Coverage- Global
* Head and Neck Cancer Companies- Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., and others.
* Head and Neck Cancer Therapies- RiMO-301, Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug, Methotrexate, Afatinib, and others.
* Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research-Access the Full Head and Neck Cancer Pipeline Analysis Today! @ Head and Neck Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Head and Neck Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Xevinapant: Debiopharm/Merck
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Tigilanol tiglate: QBiotics Group Limited
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MEM-288: Memgen, Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Head and Neck Cancer Key Companies
* Head and Neck Cancer Key Products
* Head and Neck Cancer - Unmet Needs
* Head and Neck Cancer - Market Drivers and Barriers
* Head and Neck Cancer - Future Perspectives and Conclusion
* Head and Neck Cancer Analyst Views
* Head and Neck Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=head-and-neck-cancer-pipeline-appears-robust-with-80-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Head and Neck Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4002159 • Views: …
More Releases from ABNewswire
Barry University to Host Workshop on Energy Transitions Research with Florida Po …
Alfred P. Sloan Foundation-funded study results to be presented at Orlando symposium
Orlando, Fla. - Barry University School of Law will host the Just Energy Transitions & Place [https://jetplace.org/] Workshop on Friday, October 3, 2025, at Orlando City Hall, presenting findings from a three-year research initiative that examined energy system transformations across four diverse American states.
The $500,000 study, funded by the Alfred P. Sloan Foundation, was conducted collaboratively by researchers from…
MCapitalMgt.com Reports Surge in Advisor Use of Liquid Alternative Assets for Cl …
Over the past decade, there has been a notable rise in investor interest in alternative liquid investments [https://www.mcapitalmgt.com/], driven largely by heightened market volatility, historically low interest rates, and a desire for enhanced downside protection. These investments-often referred to as "liquid alternatives" or "liquid alts"-offer a unique middle ground between traditional mutual funds and hedge funds. They aim to provide investors with exposure to sophisticated strategies while preserving the accessibility…
Black Tie Entertainment Celebrates 45+ Years of Wedding Excellence in the DMV Re …
With thousands of five-star reviews and industry accolades, the company blends tradition and innovation to deliver unforgettable experiences.
For over four decades, Black Tie Entertainment has been at the heart of extraordinary celebrations across Northern Virginia, Richmond, Charlottesville, Washington, DC, Maryland, and beyond. Founded in 1978, the company has evolved from a humble DJ business into a comprehensive entertainment brand, renowned for professionalism, meticulous attention to detail, and an unwavering commitment…
Hypoparathyroidism Market to Experience Notable Growth in Forecast Span by 2034, …
The Key Hypoparathyroidism Companies in the market include - Ascendis Pharma, EnteraBio, Bridgebio/Calcil ytix Therapeutics, Shire, and others.
DelveInsight's "Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hypoparathyroidism market outlook, drug uptake, treatment scenario…
More Releases for Head
Green Dot Sign® Going Head-to-Head with Traditional Plastic ADA Signs
After the success of their groundbreaking sustainable ADA compliant interior signs, Green Dot Sign® is now offering a more affordable and adaptable option than ever before: Low profile office signs.
Nussbaum started considering environmentally-friendly manufacturing methods and products while working at his prior sign company. The idea to create signage from a wood base and non-toxic 3D printed material for lettering, braille, and pictograms was sparked by a braille sign with…
China and India are growing head to head in Companion Diagnostic market
“Asia-Pacific Companion Diagnostics Market" research report, published by Market Data Forecast estimates that the market is growing with a CAGR of 27.91% to reach USD 2.17 billion by 2021, from USD 0.63 billion in 2016, which amounts to a cumulative growth of USD 1.54 billion.
A companion diagnostics device is a medical device that provides information which is necessary for drug safety and effectives or any other biological product. This helps…
East and West going head to head in Asia-Pacific Food Emulsifiers Market
Asia-Pacific Food Emulsifiers Market" research report, published by Market Data Forecast delineates that the market is growing with a CAGR of 6.15% to reach USD 0.78 billion by 2021, from USD 0.58 billion in 2016, which amounts to a cumulative growth of USD 0.20 billion.
View Full Report at http://www.marketdataforecast.com/market-reports/asia-pacific-food-emulsifiers-market-564/
Download Free Sample report at http://www.marketdataforecast.com/market-reports/asia-pacific-food-emulsifiers-market-564/request-sample
A substance used in food manufacturing which helps to combine liquids of different thicknesses is known as…
dinCloud Earns Top Marks in Head-to-Head Comparison
The #1 Brand in Hosted Virtual Desktops
LOS ANGELES, CA – June 19, 2012 – dinCloud, a cloud transformation company and provider of hosted virtual desktops, has come out on top as the leading provider of DaaS (Desktop as a Service) in a head-to-head comparison of five market leaders by ExtremeLabs. dinCloud’s solution received the groupings highest marks for the solution’s good control, as well as fast response, and was the…
University Students go head to head in University of Bolton’s “Sports Fiesta …
The University of Bolton Student’s Council and the Student Activities Department organized an integrated program of sporting activities around the theme "Sports Fiesta 2012" which drew a number of Universities from the Northern Emirates and Dubai.
The activities took place at UOB RAK Campus. Separate activities for male and female attendees included; badminton, basketball, chess, cricket, darts, tug-o-war, sprint race, football and volleyball matches, and other recreational games.
To coincide with the…
KnowledgetoAction Departments Go Head to Head in a Bowling Competition
London, UK ( ) October 25, 2010 - Employees of KnowledgetoAction (http://knowledgeandaction.co.uk) have been going head to head against each other in a series of team building competitions that began on September 1, 2010. Knowledge to Action believes strongly in team building and this event showcased their desire for excellent team cooperation and communication between departments, allowing for more cohesiveness within Knowledge to Action.
Most recently, each of the KnowledgetoAction…
